---
title: "ProMIS Neurosciences GAAP EPS of -$22.61 misses by $2.57"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280469972.md"
description: "ProMIS Neurosciences GAAP EPS of -$22.61 misses by $2.57"
datetime: "2026-03-25T12:12:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280469972.md)
  - [en](https://longbridge.com/en/news/280469972.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280469972.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280469972.md) | [English](https://longbridge.com/en/news/280469972.md)


# ProMIS Neurosciences GAAP EPS of -$22.61 misses by $2.57


### 相關股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [ProMIS Neurosciences (PMN.US)](https://longbridge.com/zh-HK/quote/PMN.US.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Alto Neuroscience (ANRO.US)](https://longbridge.com/zh-HK/quote/ANRO.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Minerva Neurosciences (NERV.US)](https://longbridge.com/zh-HK/quote/NERV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)

## 相關資訊與研究

- [Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06](https://longbridge.com/zh-HK/news/280788653.md)
- [Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback](https://longbridge.com/zh-HK/news/281428314.md)
- [Alto Neuros Reports Topline Phase 2 Data for ALTO-101; ALTO-207 Phase 2b on Track, $275M Cash](https://longbridge.com/zh-HK/news/281423880.md)
- [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-HK/news/281025352.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-HK/news/281015927.md)